• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dasatinib maintenance following allogeneic transplantation in acute myeloid leukemia with KIT mutation.

作者信息

Ngo Dat, Blackmon Amanda, Al Malki Monzr M

机构信息

Department of Pharmacy, City of Hope, Duarte, CA, USA.

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.

出版信息

Bone Marrow Transplant. 2025 Jan;60(1):83-85. doi: 10.1038/s41409-024-02425-w. Epub 2024 Oct 8.

DOI:10.1038/s41409-024-02425-w
PMID:39379697
Abstract
摘要

相似文献

1
Dasatinib maintenance following allogeneic transplantation in acute myeloid leukemia with KIT mutation.达沙替尼用于KIT突变的急性髓性白血病异基因移植后的维持治疗。
Bone Marrow Transplant. 2025 Jan;60(1):83-85. doi: 10.1038/s41409-024-02425-w. Epub 2024 Oct 8.
2
Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V.化疗和达沙替尼可使伴有KIT D816V的系统性肥大细胞增多症合并急性髓系白血病获得长期血液学和分子学缓解。
Leuk Res. 2009 May;33(5):735-41. doi: 10.1016/j.leukres.2008.09.027. Epub 2008 Nov 4.
3
Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial.达沙替尼用于首次完全缓解的高危核心结合因子急性髓系白血病：一项法国急性髓系白血病协作组试验
Haematologica. 2015 Jun;100(6):780-5. doi: 10.3324/haematol.2014.114884. Epub 2015 Feb 24.
4
[Analysis of the therapeutic effect of avatinib bridged allogeneic hematopoietic stem cell transplantation on 7 cases of recurrent/refractory RUNX1-RUNX1T1 positive acute myeloid leukemia with KIT mutations].阿伐替尼桥接异基因造血干细胞移植治疗7例复发/难治性RUNX1-RUNX1T1阳性且伴有KIT突变的急性髓系白血病的疗效分析
Zhonghua Xue Ye Xue Za Zhi. 2024 Aug 14;45(8):767-771. doi: 10.3760/cma.j.cn121090-20240526-00188.
5
Transitory dasatinib-resistant states in KIT(mut) t(8;21) acute myeloid leukemia cells correlate with altered KIT expression.KIT(mut) t(8;21) 急性髓系白血病细胞中的瞬时达沙替尼耐药状态与 KIT 表达改变相关。
Exp Hematol. 2014 Feb;42(2):90-100. doi: 10.1016/j.exphem.2013.10.006. Epub 2013 Nov 6.
6
Pre- and post-transplant ponatinib for a patient with acute megakaryoblastic blast phase chronic myeloid leukemia with T315I mutation who underwent allogeneic hematopoietic stem cell transplantation.移植前和移植后ponatinib 治疗伴有 T315I 突变的急性巨核细胞白血病原始细胞危象期的慢性髓性白血病患者，该患者接受了异基因造血干细胞移植。
Int J Hematol. 2019 Jul;110(1):119-123. doi: 10.1007/s12185-019-02628-8. Epub 2019 Mar 16.
7
Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death.达沙替尼和罗地替尼通过靶向 c-KIT（CD117）促进急性髓系白血病细胞死亡。
Sci Rep. 2017 Nov 10;7(1):15278. doi: 10.1038/s41598-017-15492-5.
8
Synergistic Targeting of DNA-PK and KIT Signaling Pathways in KIT Mutant Acute Myeloid Leukemia.DNA-PK 和 KIT 信号通路在 KIT 突变急性髓系白血病中的协同靶向作用。
Mol Cell Proteomics. 2023 Mar;22(3):100503. doi: 10.1016/j.mcpro.2023.100503. Epub 2023 Jan 20.
9
Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.诊断时WT1转录水平低预示着接受化疗或异基因造血干细胞移植的t(8;21)急性髓系白血病患者预后不良。
Chin J Cancer. 2016 May 19;35:46. doi: 10.1186/s40880-016-0110-6.
10
Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion.达沙替尼诱导费城染色体阳性急性淋巴细胞白血病对既往含伊马替尼方案耐药患者异基因造血干细胞移植后完全分子缓解：1 例病例报告并讨论
Med Oncol. 2010 Dec;27(4):1123-6. doi: 10.1007/s12032-009-9347-0. Epub 2009 Nov 3.

本文引用的文献

1
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of .吉特替尼作为伴有. 内部串联重复突变的 AML 移植后维持治疗。
J Clin Oncol. 2024 May 20;42(15):1766-1775. doi: 10.1200/JCO.23.02474. Epub 2024 Mar 12.
2
Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia.异柠檬酸脱氢酶 1 突变型急性髓系白血病异基因造血细胞移植后伊维替尼维持治疗的多中心 I 期临床试验。
Clin Cancer Res. 2023 Jun 1;29(11):2034-2042. doi: 10.1158/1078-0432.CCR-23-0182.
3
Risk factors for post-transplant relapse and survival in younger adult patients with t(8;21)(q22;q22) acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: A multicenter retrospective study.
接受异基因造血干细胞移植的t(8;21)(q22;q22)急性髓系白血病年轻成年患者移植后复发和生存的危险因素：一项多中心回顾性研究。
Front Oncol. 2023 Feb 9;13:1138853. doi: 10.3389/fonc.2023.1138853. eCollection 2023.
4
Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies.依尼西尼布作为异基因造血细胞移植治疗 IDH2 突变型髓系恶性肿瘤的维持治疗。
Blood Adv. 2022 Nov 22;6(22):5857-5865. doi: 10.1182/bloodadvances.2022008632.
5
How I treat with maintenance therapy after allogeneic HCT.异基因造血干细胞移植后我如何进行维持治疗。
Blood. 2023 Jan 5;141(1):39-48. doi: 10.1182/blood.2021012412.
6
Core binding factor acute myelogenous leukemia-2021 treatment algorithm.核心结合因子急性髓系白血病-2021 治疗算法。
Blood Cancer J. 2021 Jun 16;11(6):114. doi: 10.1038/s41408-021-00503-6.
7
Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL.异基因造血细胞移植后 TKI 在费城染色体阳性 ALL 中的作用。
Blood. 2020 Oct 8;136(15):1786-1789. doi: 10.1182/blood.2019004685.
8
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801.达沙替尼联合化疗用于初治核心结合因子急性髓系白血病：癌症和白血病B组研究10801
Blood Adv. 2020 Feb 25;4(4):696-705. doi: 10.1182/bloodadvances.2019000492.
9
Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.前瞻性评估 KIT 突变对伴有 RUNX1-RUNX1T1 和 CBFB-MYH11 的急性髓系白血病的预后影响。
Blood Adv. 2020 Jan 14;4(1):66-75. doi: 10.1182/bloodadvances.2019000709.
10
Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.同种异体干细胞移植治疗核心结合因子急性髓系白血病第二次完全缓解：来自欧洲血液和骨髓移植学会急性白血病工作组的一项研究。
Haematologica. 2020 Jun;105(6):1723-1730. doi: 10.3324/haematol.2019.222810. Epub 2019 Aug 22.